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DOI 10.1186/s13023-015-0292-zRESEARCH Open AccessDiffuse left ventricular interstitial fibrosis is
associated with sub-clinical myocardial dysfunction
in Alström Syndrome: an observational study
Nicola C. Edwards1,2*, William E. Moody1,2, Mengshi Yuan1, Adrian T. Warfield3, Robert Cramb4, Richard B. Paisey5,
Tarekegn Geberhiwot6 and Richard P. Steeds1,2Abstract
Background: Alström syndrome is a rare inherited ciliopathy with progressive multisystem involvement. Dilated
cardiomyopathy is common in infancy and recurs or presents de novo in adults with high rates of premature
cardiovascular death. Although Alström syndrome is characterised by fibrosis in solid organs such as the liver, the
pathogenesis of related cardiomyopathy are not clear. To date it is not known whether diffuse interstitial myocardial
fibrosis is present before the onset of heart failure symptoms or changes in conventional parameters of left ventricular
function.
Methods: In this observational study, 26 patients with Alström syndrome (mean age 27 ± 9 years, 65 % male, 24 h
ABPM 130 ± 14 / 77 ± 9 mmHg) without symptomatic cardiovascular disease were recruited from a single centre and
compared to matched healthy controls. All subjects underwent cardiac MRI (1.5 T) to assess ventricular function, diffuse
interstitial myocardial fibrosis by measurement of extracellular volume on T1-mapping (MOLLI) and coarse replacement
fibrosis using standard late gadolinium enhancement imaging.
Results: Global extracellular volume was increased in Alström syndrome with wider variation compared to controls
(0.30 ± 0.05 vs. 0.25 ± 0.01, p < 0.05). Left ventricular long axis function and global longitudinal strain were impaired in
Alström syndrome without change in ejection fraction, ventricular size or atrial stress (NT-proBNP) (p < 0.05). Global
extracellular volume was associated with reduced peak systolic longitudinal strain (r = −0.73, p < 0.01) and strain rate
(r = −0.57, p < 0.01), increased QTc interval (r = 0.49, p < 0.05) and serum triglycerides (r = 0.66, p < 0.01). Nine (35 %)
patients had diffuse mid-wall late gadolinium enhancement in a non-coronary artery distribution.
Conclusion: Diffuse interstitial myocardial fibrosis is common in Alström syndrome and is associated with impaired left
ventricular systolic function. Serial studies are required to determine whether global extracellular volume may be an
independent imaging biomarker of vulnerability to dilated cardiomyopathy and heart failure.
Keywords: Alström syndrome, Myocardial fibrosis, Cardiac MRI, T1 mapping, Left ventricular functionBackground
Alström syndrome (ALMS) is a rare autosomal recessive
syndrome (OMIM 203800) characterised by childhood
onset retinal cone rod dystrophy, neuronal hearing loss,
obesity and severe insulin resistance presenting with
exaggerated features of the metabolic syndrome [1–4].* Correspondence: n.c.edwards@bham.ac.uk
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any medium, provided the original work is pr
(http://creativecommons.org/publicdomain/zeEstimates of the prevalence range from 1:10,000 [5] to
fewer than 1:1,000,000 [6]. About 800 individuals diagnosed
with ALMS have been identified worldwide. Idiopathic
infantile dilated cardiomyopathy (ICM) presents acutely in
nearly half of all ALMS subjects within the first few weeks
of life [7, 8]. In survivors, the pathological process then
appears to be fully reversible, as there are no persisting
clinical, electrocardiographic or echocardiographic evidence
of ventricular dysfunction, nor is there evidence of coarse
myocardial fibrosis [8]. Cardiomyopathy may then recur or
develop de novo in up to 65 % of adolescents and adultsarticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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coarse fibrosis is evident on post-mortem [9]. This has also
been demonstrated as patchy late gadolinium enhancement
(LGE) using cardiac magnetic resonance imaging (CMR)
[10, 11]. Although ALMS is characterised by diffuse fibrosis
in other solid organs, there are only limited data identifying
whether diffuse interstitial fibrosis may be present in the
myocardium before onset of dilated cardiomyopathy [10].
Diffuse interstitial fibrosis may be missed on conventional
late gadolinium enhancement (LGE) imaging, which relies
on comparison of signal intensities between normal and
abnormal myocardium within the same image [12]. This
limitation is overcome with newer CMR T1-mapping
techniques which can quantify the size of the extracellular
volume (ECV). The primary aims of this study were; 1) to
establish whether diffuse interstitial myocardial fibrosis is
present in asymptomatic adult subjects with ALMS, 2) if
present, determine whether this is associated with change
in left ventricular function.
The profound metabolic disturbances which characterise
ALMS include severe insulin resistance, activation of the
renin angiotensin aldosterone system and raised serum
triglycerides - each of which has a potential role in the
development of myocardial fibrosis [2, 13–15]. Thus,
although ALMS is rare, it offers a model of disease
processes, including metabolic syndrome, that are of
increasing importance to a much wider population. A
secondary aim of this study was to identify associations
between potential metabolic changes in ALMS that might
mediate myocardial fibrosis.
Methods
Study design
A propsoective cohort observational study performed
between March 2012 and November 2013.
Patients & setting
In total, 26 consecutive adults with genetically proven
ALMS attending the National Centre for Rare Disease at
the Queen Elizabeth Hospital Birmingham, England
were studied prospectively as part of standard clinical
care. Two other patients were seen at the National Centre
during this time period but did not proceed with CMR
due to contra-indications (one permanent pacemaker; one
with a cochlear implant). Patients were compared to
gender and age matched healthy controls with no history
of cardiac disease recruited as part of an on-going clinical
study [16].
Ethics statement
This study was approved by the National Research Ethics
Service and all patients provided written informed consent
to participate (12/WM/0250).Cardiac MRI
Consent was obtained for contrast enhanced CMR
(1.5 T Avanto, Siemens Healthcare, Erlangen, Germany).
Left ventricular (LV) dimensions, volumes and mass were
acquired in line with standard CMR protocols [17]. Mitral
annular plane systolic excursion (MAPSE) were measured
on standard 4-chamber SSFP cine images, using the
straight-line distance travelled by the lateral mitral annulus
from end-diastole to end-systole. CMR-tagging (SPAMM)
was performed in the horizontal long-axis (4 chamber)
image using prospective electrocardiographic gating
[18]. Late enhancement (LGE) imaging was performed
7–10 min after 0.15 mmol/Kg of gadolinium contrast
bolus (Gadovist Bayer Health Care). LGE is an imaging
technique that characterizes the myocardium by detecting
patterns of disease including reparative fibrosis and infarc-
tion. Differences in the “wash out” kinetics of damaged
myocardium creates relative differences in signal intensity
within the myocardium to highlight areas that are abnormal
(white) compared to areas that are normal (black). These
white areas correspond to macroscopic reparative fibrosis.
The technique is reliant on the heart containing areas of
normal myocardium to reveal the difference in signal
intensity – which is one reason why the technique
may fail to detect diffuse myocardial disease throughout the
ventricle. T1 mapping is a newer technique which has the
advantage that there is no need for “normal” myocardium
against which to compare T1 values within the same heart
and is thus capable of detecting diffuse fibrosis, as has been
shown in other conditions [9] and is postulated in ALMS.
Therefore, in addition to standard LGE, short-axis images
at LV basal and mid-ventricular levels were acquired using
an ECG-gated modified Look-Locker inversion recovery
sequence (MOLLI) sequence for T1 mapping before con-
trast and at 15–20 min after bolus contrast administration
[19]. No patient had complications arising from the use of
Gadolinium contrast.
CMR image analysis
Analysis was performed off-line using Argus Software
(Siemens®) according to the Society for Cardiovascular MR
guidelines for reporting CMR with parameters indexed to
height and body surface area where appropriate [20].
Tagged images were analyzed with CIMTag2D software
(Cardiac Image Modelling, University of Auckland,
Auckland) to calculate global peak systolic strain,
peak systolic strain rate (myocardial deformation) and
peak early diastolic strain rate (an indicator of diastolic
function) [18].
Quantitative parametric images of myocardial ECV were
generated with manual contouring to define a region of
interest (ROI) within the LV myocardium in the ventricular
septum (4-chamber view) and at basal and mid ventricular
level (short-axis) on matched pre and post contrast images
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contaminating T1 measurements at the myocardial-blood
pool interface. T1 time in each ROI was recorded and used
to calculate myocardial extracellular volume (ECV) by
validated formulae [21].
ECV ¼ ΔR1 myocardiumð Þ= ΔR1 blood poolð Þð Þ 1‐Hctð Þ
HCT refers to the haematocrit recorded on a venous
blood sample at the time of scan, ΔR1 = 1/T1 post
contrast – 1/T1 pre contrast. The ECV was assessed
in the left ventricle from the basal and mid ventricular
levels, averaged to yield a “global ECV” measurement.
Further details on the methods used have been pub-
lished [21, 22].
Biochemistry
Venous blood samples were collected for routine haema-
tology, biochemistry and lipid profiles. Serum N-terminal
pro B Natriuretic peptide (NT-proBNP, ng/L) was mea-
sured by sandwich immunoassay with magnetic particle
separation and chemiluminescent detection on an E170
analyser (Roche Diagnostics, Burgess Hill) with a lower
limit of detection of 0.6 pmol/L. Plasma renin was
measured using an immunoradiometric assay (Cis Bio,
IBA Molecular UK, Guildford) with age and position
reference intervals and a detection limit of 5 ng/L.
Aldosterone was measured by competitive radio-
immunoassay (Coat-a-Count, Siemens Medical Solutions
Diagnositics, Llanberis.) which has reference intervals
dependent on position with a detection limit of 60 pmol/L.
C-peptide (pmol/L)/insulin (pmol/L) were also measured
(Royal Surrey County Hospital, Guildford).
Blood pressure
Subjects underwent 24 h ambulatory blood pressure
monitoring using a British Society of Hypertension
approved protocol [23].
Electrocardiogram
Standard 12-lead electrocardiograms were recorded in each
subject within 24 h of the CMR scan, with measurement of
PR interval, QRS duration and QTc intervals using standard
methodology (Bazett’s formula for QTc).
Statistical analysis
Continuous variables are expressed as mean ± standard
deviation (SD) if normally distributed or median (inter-
quartile range) if non-normally distributed by the
Shapiro-Wilk test. Paired group comparisons were
performed using independent T-test, Mann–Whitney and
one-way analysis if variance with Bonferroni post hoc
tests, as appropriate. Correlations between variables were
assessed by Pearson if normally distributed and Spearmananalyses if non-normally distributed. A multivariable re-
gression model was used to assess predictors of ECV
using variables associated with myocardial fibrosis.
Statistical tests were two tailed and a p-value <0.05
was considered to indicate statistical significance.
Results
In total, 26 ALMS patients were compared with healthy
controls (mean age 27 ± 9 vs. 27 ± 6 years, p = 0.24). Subject
genetic and demographic profiles are presented in Table 1
and Table 2 respectively. A history of infantile cardiomyop-
athy was documented in eight ALMS patients. One patient
had end-stage renal disease (ESRD) requiring dialysis. One
patient had a history of prior myocardial infarction.
All patients were NYHA class I.
Patients with ALMS demonstrated marked metabolic
derangements (Table 2). All were insulin resistant.
Seventeen patients had diabetes and five patients had
impaired glycaemia. Mean C-peptide: Glucose ratio
(a marker of insulin resistance) was increased. Serum
triglyceride levels were also elevated with reduced
serum HDL levels compared to controls. NT-proBNP
was increased above normal range (>200 ng/L) in only
2 patients. One of these patients had ESRD and the
subject was below the threshold for diagnosis of heart
failure (<400 ng/L).
Cardiovascular structure, function & tissue
characterization
Ventricular volumes and function
Patients with ALMS had reduced absolute and indexed
LV volumes compared to controls but did not differ
when indexed for height (to allow for obesity). Absolute
LV mass did not differ between groups but was increased
when indexed to height2.7. There was no difference in LV
ejection fraction (EF) but longitudinal function (MAPSE)
was reduced (Table 3).
Myocardial tagging
Left ventricular global longitudinal peak systolic strain
and strain rate were reduced in ALMS (Table 3).
T1 mapping
Mean global ECV was increased compared to controls
(Table 3) but with wider variation and cross-over with the
normal population at the lower end of the range (Fig. 1).
Patients with ALMS had reduced LV longitudinal function
(MAPSE 12 mm ±2 vs. 17 mm± 2, p < 0.01), reduced
global longitudinal strain (11.2 % ± 2.6 vs. 14.7 % ± 2.3,
p < 0.01), strain rate (0.58 s−1 ± 0.11 vs. 0.83 s−1 ± 0.15,
p < 0.01) and reduced early diastolic strain rate (0.49 ±
0.18 s−1 vs. 0.62 ± 0.15 s−1, p < 0.05). Fourteen patients
(54 %) had an ECV above the upper limit (0.279) for
controls. Five patients had ECV above the upper limit
Table 1 Individual patient demographic profile
Patient Age Gender Ethnicity BMI ALMS Protein ALMS Protein Infantile
CMmutation change mutation change
1 21 Male White British 32.6 c.6526C > T p.Gln2176X c.11101C > T p.Arg3701X Yes
2 19 Male White British 27.1 c.6526C > T p.Gln2176X c.11101C > T p.Arg3701X No
3 18 Male White British 32.3 c.8932C > T p.GLN2978X c.5356A > G p.ASN1786Asp Yes
4 17 Male White British 26.4 c.10769delC p.Thr3590LysfsX6 c.5356A > G p.Asn1786Asp Yes
5 20 Male White British 31.5 c6526C > T p.Gln217X c11101C > T pArg3701X No
6 49 Male White British 31.9 c.10483C > T p.Gln3495X c.10775delC P.Threo3592LysfsX6 No
7 40 Male White British 38.4 c.1729delA p.Arg577Glyfsx17 c.10477C > T p.Gln3493X No
8 25 Female Mixed race 30.0 c.2218dupA p.ThreoAsnfsX2 c.1069C > T p.Arg3657X No
9 45 Male White British 35.3 c.1874A > G p.His623Arg No
10# 44 Male White British 28.2 c.10769delC p.Thr3590LysfsX6 c.11410C > T p.Arg38404X Yes
11 21 Female White British 26.4 c6584delA p.Lys2195SerfX10 C1008_1009delT pCys336fsX1 Yes
12 22 Female White British 27.6 c.6823C > T p.Arg2275X c.9535C > T P.Arg3179X No
13 26 Male White British 22.7 c.6823C > T p.Arg2275X c.9535C > T P.Arg3179X No
14 29 Male White British 31.6 c.6895delG p.val2299TrpsX43 c.11443C > T p.Gln3815X No
15 43 Male White British 35.2 c.8995C > T p.Gln3493X c>9001C > T Gln3001 No
16 29 Female White British 27.0 c.8002C > T p.arg2668X c.10879C > T pArg3627x No
17 18 Male BritishPakistani 27.8 c.4937C > A p.Ser1646X No
18 20 Male BritishPakistani 36.6 c.7544-200_767 + 1110del No
19 19 Male BritishPakistani 26.8 c.7544-200_767 + 1110del Yes
20 21 Female BritishPakistani 29.6 c.5075delC p.Pro1692LeufsX39 c.5075delC p.Pro1692LeufsX39 Yes
21 24 Female White British 26.5 Result awaited* - - - No
22 20 Male BritishPakistani 25.9 c.4937C > A p.Ser2646STOP Yes
23 19 Female British Indian 19.4 c.2041C > T p.Arg681X c.2041C > T p.Arg681X Yes
24 23 Male British Indian 28.9 c.2041C > T p.Arg681X c.2041C > T p.Arg681X No
25 32 Female White British 25.7 C11101C > T p.R3701X No
26 20 Female White Australian 37.7 c.7911dupC p.Asn2638Glnfs24 No
#End-stage kidney disease on dialysis
*Genetic data pending at time of publication. Patient fulfills the clinical diagnostic criteria for ALMS on serial assessment
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(Table 3). There was no difference in mean pre-
contrast myocardial T1 times between ALMS and
controls (Table 3). Indeed, 11 ALMS patients (41 %)
had T1 times within the range for matched controls
(943 ms). Post contrast T1 times were reduced in
ALMS (Table 3).
Late gadolinium enhancement
Late gadolinium enhancement in a diffuse, non-coronary
artery pattern was present in 9 (35 %) patients with
ALMS (two with a history of infantile cardiomyopathy).
An example is shown in Fig. 2. Compared to ALMS
subjects with no LGE but increased ECV, subjects
with LGE did not have increased ECV (0.34 ± 0.05 vs.
0.31 ± 0.03, p = 0.22) and no differences in LV volumes,
ejection fraction or deformation (Table 3).ECG
All ALMS patients were in sinus rhythm with normal
atrial activation (PR interval 143 ms ± 16), ventricular
depolarisation (QRS duration 88 ms ± 16) and ventricular
repolarisation (QTc 416 ms ± 24 and 426 ms ± 24 for
males and females respectively). Patients with ECV above
the upper limit of the range for matched controls had
increased QTc (430 ± 21 ms vs. 412 ± 18 ms, p < 0.05).
Myocardial fibrosis
ECV correlated with age (r = 0.50, p < 0.05), global longitu-
dinal peak systolic strain (r = −0.73, p < 0.01), peak systolic
strain rate (r = −0.57, p < 0.01), MAPSE (r = −0.39, p < 0.05),
but not ejection fraction, NT-BNP or LV mass/height2.7.
Serum triglycerides (r = 0.66, p < 0.01) and QTc (r = 0.49,
p < 0.05) also correlated with ECV (Fig. 3). These factors
were entered into a multivariable linear regression model
Table 2 Demographic, haemodynamic and biochemical data
Controls ALMS
Number n 26 26
Age years 27 ± 6 27 ± 9
Male n (%) 17 (65 %) 17 (65 %)
Height (m) 1.74 ± 0.09 1.61 ± 0.09**
Weight (Kg) 76 ± 16 77 ± 16
Body Mass Index 25 ± 4 30 ± 5**
Haemoglobin (g/dL) 14.3 ± 1.2 14.0 ± 2.2
eGFR (ml/min/1.73 m2) 87 ± 8 73 ± 25*
Renin (pg/ml) a - 41 (18–153)
Aldosterone (pg/ml) a - 97 (67–220)
NT-pro BNP (ng/L) a 38 (4–75) 37 (17–89)
Cholesterol (mmol/L) 4.6 (0.8) 5.1 ± 1.3
Triglycerides (mmol/L) a 1.0 (0.6–1.4) 2.5 (1.5–4.1)**
High Density Lipoprotein (mmol/L) 1.4 (0.3) 0.9 ± 0.3**
Glucose (mmol/L) a 4.7 (4.2–5.0) 6.1 (4.6–15.0)*
HbA1c (%) - 7.9 ± 2.7
Insulin (pmol/L) a - 858 (239–1760)
C-peptide:Glucose ratio (ng/ml:mg/dl) a - 4.2 (2.2–6.2)
ACR (mg/mmol) a 0.1 (0.05–0.2) 1.5 (0.25–34)
Urate (mmol/L) 286 ± 67 409 ± 111*
24 h daytime SBP (mmHg) 119 ± 9 130 ± 14*
24 h daytime DBP (mmHg) 72 ± 7 77 ± 9*
ACR albumin/creatinine ratio, ALMS Alström Syndrome, DBP diastolic blood
pressure, eGFR Estimated glomerular filtration rate, HBA1c glycated
haemoglobin, NT-pro BNP N-terminal pro B natriuretic peptide, SBP systolic
blood pressure
Value ± standard deviation, amedian (inter-quartile range), p = * < 0.05,
p = ** <0.01
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Global longitudinal strain remained an independent pre-
dictor of ECV (unstandardized β coefficient −0.01, 95 %
CI −0.02-0.004, p < 0.01).
Patient events
Two patients (Table 1: patient 7 aged 40 and patient 10
aged 44 years) died over the study period. Both deaths
occurred unexpectedly following a short respiratory tract
infection which led to cardiac decompensation and
multi-organ failure in the intensive care setting. Neither
patient had a history of infantile cardiomyopathy but
both had a history of severe hypertriglyceridaemia in
teenage years (>50 mmol/l) with pancreatitis and
raised plasma renin (>3000 ng/L) when normotensive.
Furthermore, both had extensive patchy LGE on CMR,
elevated global ECV (0.33 and 0.41 respectively) and
reduced myocardial deformation despite a normal LV
ejection fraction. On autopsy of one patient, there was
extensive fibrosis in a non-ischaemic pattern in the RVwhich corresponded with the extensive LGE on CMR
(Fig. 4) and evidence of a chronically occluded right
coronary artery with extensive collateralisation.
Discussion
Interstitial myocardial fibrosis assessed using CMR T1
mapping, was evident in over 50 % of patients with
ALMS. Coarse fibrosis within the LV myocardium was
detected in keeping with previous reports but a further
20 % of patients were shown to have interstitial fibrosis
missed using conventional LGE alone. Expansion of the
ECV was associated with impaired global LV systolic
deformation, impaired LV diastolic function and increased
QT interval.. Impairment of global longitudinal strain and
strain rate preceded any change in ejection fraction and
without abnormality of conventional markers of elevated
LV end-diastolic pressure and atrial stretch, including
both NT pro-BNP and left atrial volume. This finding
raises the possibility that surveillance of ALMS for
evidence of cardiomyopathy using NT pro-BNP may
be inadequate. In contrast to previous echocardiographic
studies [24] that have reported ‘low-normal’ LV ejection
fraction, use of CMR in young adults with ALMS indicates
that patients have equivalent conventional values of
ventricular size and EF to healthy controls but re-
duced myocardial deformation and diastolic function.
These data support the concept that expansion of the
ECV and reduced myocardial deformation may be
more powerful predictors of adverse cardiovascular
outcome than ejection fraction [22].
Although ALMS is a rare autosomal recessive genetic
disorder, there is much interest in understanding the
disease as a monogenic model for end-organ fibrosis
which has been proven to affect the liver and kidneys
[4]. The increase in diffuse interstitial myocardial fibrosis
(as measured by ECV) and prolongation of the QTc
interval on 12 lead electrocardiograms in this study
are consistent with the limited autopsy data available
in 5 ALMS patients in whom moderate to severe
interstitial myocardial fibrosis was found [9]. The data
are also consistent with a smaller study of 8 patients,
only 3 of whom had normal LVEF at the time of CMR, in
which T1 scout sequences were used to identify lower
pre-contrast T1 relaxation as a measure of diffuse fibrosis
[10]. Further studies using T1-mapping have demon-
strated that diffuse interstitial fibrosis is prominent in dia-
betic patients [25], correlates with insulin resistance [26]
and is associated with adverse prognosis [27]. In keeping
with these data, our ALMS cohort displayed shorter myo-
cardial post contrast T1 times and reduced deformation
which is not unexpected given the high prevalence of im-
paired glycaemia. Furthermore, the correlation between
expansion of the ECV and elevated triglycerides in our
study may be consistent with poor diabetic control and
Table 3 Cardiac MRI Functional and Fibrosis data
Controls ALMS ALMS
ECV < ULN ECV > ULN ECV > ULN
NO LGE LGE
Number n 26 26 12 5 9
Mean global ECV 0.25 ± 0.01 0.30 ± 0.05* 0.25 ± 0.02 0.31 ± 0.03a 0.34 ± 0.05b
Global pre contrast T1 (ms) 970 ± 11 949 ± 35 934 ± 34 952 ± 33 972 ± 35
Global post contrast T1 (ms) 522 ± 58 465 ± 61* 472 ± 54 440 ± 47 437 ± 43
Diffuse LGE n 0 9 0 0 9
LVEDV (ml) 133 ± 29 105 ± 23** 107 ± 31 100 ± 13 108 ± 25
LVEDV index (ml/m2) 69 ± 12 57 ± 11** 57 ± 13 56 ± 11 58 ± 13
LVESV(ml) 43 ± 13 38 ± 15 37 ± 15 32 ± 8 43 ± 19
LVESV index (ml/m2) 22 ± 6 20 ± 8 20 ± 7 18 ± 5 23 ± 10
LVEF (%) 68 ± 5 66 ± 8 67 ± 7 69 ± 5 62 ± 11
LV mass (g) 115 ± 31 104 ± 27 106 ± 27 87 ± 13 112 ± 34
LV mass index (g/m2) 60 ± 14 56 ± 12 56 ± 10 48 ± 8 60 ± 16
LV mass/ Height2.7 (g/m2.7) 25 ± 6 29 ± 7* 28 ± 6 24 ± 6 32 ± 9
LA volume (ml/m2) 33 ± 8 35 ± 15 29 ± 8 40 ± 14 39 ± 15
MAPSE (mm) 17 ± 2 12 ± 2* 13 ± 2 13 ± 3 11 ± 3
Global long SS (%) 14.7 ± 2.3 11.2 ± 2.6** 12.9 ± 1.0 10.9 ± 2.0a 9.6 ± 1.9b
Global long SSR (s−1) 0.83 ± 0.15 0.57 ± 0.11** 0.63 ± 0.16 0.53 ± 0.11a 0.52. ± 0.15b
Global long ESR (s−1) 0.62 ± 0.15 0.49 ± 0.18* 0.54 ± 0.15 0.44 ± 0.19 0.41 ± 0.19
EDV end-diastolic volume, ESV end-systolic volume, EF ejection fraction, LA left atrium, LGE late gadolinium enhancement, long; longitudinal, LV left ventricle,
MAPSE mitral annular plane systolic excursion, RV right ventricle, TAPSE tricuspid annular plane systolic excursion, SS systolic strain, SR systolic strain rate, ESR early
diastolic strain rate, ULN ECV above the upper limit (0.279) observed in matched control
ap < 0.05, Bonferroni post-hoc tests for differences ECV above upper limit of normal controls vs. increased ECV no LGE
bp <0.05, Bonferroni post-hoc tests for differences ECV above upper limit of normal controls vs. increased ECV with LGE
ANOVA * p <0.05, ** <0.01, ALMS vs. controls
Fig. 1 Box scatter plots of global extracellular volume (ECV) in patients with ALMS and controls. Error bars are standard error of the mean x2.
Dashed horizontal line defines the upper value within the matched normal population (0.279). ECV was assessed in the left ventricle from the
basal and mid ventricular levels and averaged to yield a “global ECV” measurement. * p <0.05
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Fig. 2 Examples of late gadolinium enhancement and corresponding pre-contrast colour T1 maps in patients with ALMS. a Clear late enhancement
(arrow) in the basal infero-lateral wall. b Corresponding high T1 (1057 ms) on the T1-map (arrow). c No late enhancement in the left ventricular
myocardium. d Corresponding areas with high T1 (1043 ms) on the T1-map in the septum and infero-lateral wall (green)
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ism behind the development of fibrosis within the myocar-
dium is not known. It has recently been shown that
ALMS1 is an important molecule for cell cycle regulation
in perinatal cardiomyocytes and that deficiency of the
protein may lead to a mitogenic cardiomyopathy [28].
This was supported by the histological diagnosis of
mitogenic cardiomyopathy in two siblings from consan-
guineous parents of Turkish origin who died in infancy
from dilated cardiomyopathy [29]. This may explain peri-
natal mortality but other mechanisms may be important
in the development of adult cardiomyopathy, such as
the onset of adiposopathy, wherein adiposite enlarge-
ment may be associated with inflammation and insulin
resistance [30].We acknowledge that while mean global ECV was
higher than controls in this study, expansion of the ECV
was not universal and there was considerable dispersion
of ECV values within the range of normal healthy
controls. Indeed, 40 % of patients had a native pre-
contrast myocardial T1 values below the cut off for
healthy volunteers (943 ms) raising the possibility of
myocardial fat deposition or pseudonormalization of
T1 due to the combined presence of lipid and fibrosis
within the LV. This significant inter-individual variation
suggests that development of fibrosis is not an inevitable
consequence of the genetic defect alone and that environ-
mental factors may also play an important role. Further
serial studies are warranted in ALMS to determine
whether those with higher ECV are susceptible to adverse
Fig. 3 Association of diffuse myocardial fibrosis with markers of lipid metabolism, systolic function and cardiac electrical activity. Scatter plots
demonstrating the association between global extracellular volume and a) global longitudinal strain, b) global systolic strain rate, c) 12 lead ECG
QTc interval and d) serum triglycerides in patients with ALMS
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case in other populations [27].
Despite the fact that ALMS patients are charac-
terised by obesity, severe insulin resistance and metabolic
syndrome [13, 2], reduction in myocardial deformation
was not due to myocardial infarction, since the distri-
bution of LGE was neither subendocardial nor con-
sistent with a coronary artery territory. It is possible
that expansion of the ECV with increased diastolic
stiffness in association with subclinical ventricular
dysfunction [31] may have contributed to the failure of
the two adult patients to survive intercurrent respiratory
tract infections, as occurred in this series. It is also
interesting to speculate whether expansion of the
ECV is responsible for prolongation of the QTc and
whether this predisposes individuals to lethal arrhythmia.
It is noteworthy that despite extensive fibrosis in the
two patients that died, both were asymptomatic before
developing a chest infection.An unusual feature of ALMS is the occurrence of
infantile cardiomyopathy within the first few months of
life which, if not fatal during the acute stage, may be
followed by an apparent complete recovery [8]. Adults
with ALMS have an increased risk of adverse cardio-
vascular outcomes but this risk does not appear to be
heightened by a history of infantile cardiomyopathy.
In our study, there was no relationship between exposure
to infantile CM and the severity of diffuse interstitial
fibrosis, presence of coarse scarring on LGE or reduction
either in LVEF or in myocardial deformation. These data
are consistent with the theory that the pathophysiology
of early (infantile) and late cardiovascular morbidity
and mortality is different. Coarse replacement fibrosis
documented with LGE does not appear to be simply
a consequence of scarring from severe cardiomyopathy in
childhood, a concept supported by two previous smaller
studies in ALMS [11, 14]. In addition, the recent work by
Shenje et al. [28] and Louw et al. [29] have suggested a
Fig. 4 Myocardial fibrosis on CMR and post-mortem specimens from a patient with ALMS. a-c) 4 chamber CMR imaging; a cine, b late
gadolinium enhancement and c T1 mapping. Note the extensive LGE in the RV (*) with corresponding low T1 on the post-contrast MOLLI.
d Corresponding macroscopic image from autopsy of the RV with strands of sub-endocardial fibrosis seen as pallor within the RV (black arrow).
e-f Corresponding low power views of part of the free wall of the right ventricle demonstrating patchy swathes of interstitial fibrosis replacing
myocardiocytes with more subtle pericellular fibrous expansion. The fibrous tissue stains pink with H&E and red with EHVG (H&E & EHVG,
original magnification X1.25). g-h Comparable intermediate magnification photomicrographs of the free wall of the right ventricle depicting
more dispersed interstitial fibrosis enclaving groups of myocytes and focally insinuating between individual muscle cells. The fibrous tissue
stains pink with H&E and red with EHVG (H&E stain, original magnification X1.25)
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cardiomyopathy, although these changes have not been
documented in adult post-mortem hearts. Inferences re-
lating to infantile cardiomyopathy from our data however
are limited by the fact that our study only included adult
survivors, since patients under the age of 16 years are
excluded from referral to the UK National Centre at Queen
Elizabeth Hospital.
Limitations
Given the small sample size and narrow age range of
patients with this rare disease, we were underpowered
to show some relationships reported previously in ECV[32]. This is a cross-sectional, observational study, and
hence it is only possible to speculate on the aetiology of
diffuse fibrosis and whether it is represents an intermedi-
ate phenotype in ALMS between cardiovascular health,
coarse myocardial fibrosis and ultimately LV failure. The
extent to which diffuse interstitial fibrosis is related to the
primary effect of the ALMS1 mutation on fibroblast
expression or to the severe metabolic disturbance
warrants further study [33, 34]. Due to the rarity of this
condition, there are relatively few available patients to
study and echocardiography is particularly limited by poor
acoustic windows in ALMS patients. In our experience,
CMR scanning takes longer and requires practice of breath
Edwards et al. Orphanet Journal of Rare Diseases  (2015) 10:83 Page 10 of 11holding techniques but is feasible in the great majority des-
pite most adult ALMS patients having both severe hearing
and visual impairment. Biomarkers would be of particular
use in ALMS given the limitations of echocardiography
and the limited availability of CMR but standard markers
of cardiovascular stress, including NT pro-BNP were not
useful. Future studies should consider the measurement of
direct markers of collagen turnover and fibrosis, such as
serum C-terminal propeptide of type I pro-collagen [35].
Conclusion
Diffuse interstitial fibrosis is common in asymptomatic
patients with ALMS and is associated with abnormalities
of LV systolic and diastolic function. The presence of
cardiac fibrosis may be actively modulated by the severity
of metabolic dysfunction, with elevated triglycerides a
potential marker or intermediary. Expansion of the ECV is
an imaging biomarker of cardiovascular vulnerability that
demands longitudinal study in ALMS.
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